PFIZER INC.

Novotech's report on gastric cancer (GC) highlights a surge in global clinical trials, with Asia-Pacific leading (52% of trials), and Mainland China accounting for 48% of the region's trials. The report identifies 228 drugs in development, with a focus on targeted and immunotherapies. GC research attracted $7.4 billion in venture capital funding from 2019 to 2023, with China and the U.S. leading in funding. Challenges include high treatment costs and the need for better patient selection, but opportunities exist in personalized medicine and liquid biopsies.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.

The weight-loss treatment market is expected to see 16 new drugs by 2029, expanding the market to $200 billion by 2031, driven by interest sparked by Novo Nordisk and Eli Lilly. Amgen and Pfizer are among companies testing their drug candidates, which could lower prices amid criticism over high costs.

E.R. received honoraria from Eli Lilly, Novartis, Seagen; travel support from Gilead, Mundipharma, Novartis, Pfizer, Roche; research funding from Gilead, Menarini, MSD. F.A. consulted/advised AstraZeneca, Daiichi–Sankyo, Lilly, Novartis, Pfizer, Relay Tx, Roche; received travel support from AstraZeneca, GlaxoSmithKline, Lilly, Novartis, Roche; research funding from AstraZeneca, Daiichi, Eli Lilly, Novartis, Pfizer, Roche.

CRISPR-Cas9 gene editing therapy Casgevy, approved for sickle cell disease, faces slow patient treatment and profitability challenges. 20 patients are 'in the funnel' but timeline for treatment remains unclear. Insurance coverage for Casgevy's $2.2 million price is uncertain, with commercial payers likely to cover first. Fertility treatments not covered by Medicare/Medicaid add complexity. Future gene therapies need streamlined manufacturing and robust clinical data for market success.

Up to 16 new GLP-1 drugs could launch by 2029, capturing nearly a third of a $200B market by 2031, dominated by Novo Nordisk and Eli Lilly. Competitors like Roche, Amgen, Pfizer, AstraZeneca, Boehringer, Viking Therapeutics, and Structure Therapeutics may launch rival weight-loss drugs within 3-4 years. Novo Nordisk and Lilly are expected to retain 68% of weight-loss sales, but the market may see price declines of 10%-15% by 2027 due to competition.

The global pharmaceutical filtration market is projected to grow from USD 12.47 billion in 2023 to USD 19.55 billion by 2033, driven by drug launches and R&D activities. North America leads with a 36.17% share, and membrane filters dominate the product type segment. Microfiltration is expected to grow at the fastest CAGR of 6.75%. Final product processing holds the largest market share of 22.54%. Challenges include high capital requirements and increased regulations.